| 10-Q: KERYX BIOPHARMACEUTICALS INC - Middle East North Africa Financial Network |
|
|
Middle East North Africa Financial Network Zerenex is currently in Phase 3 clinical development in the United States, under an SPA, as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD, on dialysis. In April 2011, our Japanese |